Table 5.
Gut hormones in patients with prediabetes of the PLC and MO groups during the intervention.
| 0 wk | 6 wk | 12 wk | GLM p # |
Rate of Change 0–12 wk (p Φ) |
||
|---|---|---|---|---|---|---|
| Ghrelin (pg/mL) | PLC | 141.7 ± 91.2 | 128.6 ± 80.4 | 99.1 ± 70.6 | 0.997 | −30.7 ± 25.7 |
| MO | 134.5 ± 92.4 | 121.8 ± 76.6 | 87.5 ± 55.8 | −30.8 ± 26.2 | ||
| NS | ||||||
| PYY (pg/mL) | PLC | 37.4 ± 26.5 | 38.5 ± 26.5 | 30.1 ± 23.7 | 0.161 | −10.3 ± 36.0 |
| MO | 34.0 ± 20.4 | 29.1 ± 22.2 | 28.0 ± 23.2 | −1.8 ± 79.1 | ||
| NS | ||||||
| GLP-1 (pg/mL) | PLC | 6.8 ± 6.6 | 6.6 ± 7.7 | 5.4 ± 5.2 | 0.876 | 18.4 ± 135.8 |
| MO | 7.2 ± 5.6 | 6.2 ± 4.8 | 6.4 ± 6.8 | 6.1 ± 110.9 | ||
| NS |
General linear model (GLM) with within-subject factor “visit”, the fixed factor “treatment” and the interaction “treatment × visit”. The p #-value corresponds to the “treatment × visit” factor. p Φ, Comparison between treatment groups by independent sample T test (Ghrelin) or Mann-Whitney U test (PYY and GLP-1). NS, not significant; PYY, peptide YY; GLP-1, glucagon-like peptide-1.